Get the Stockscreener App
4.82
2.77%
0.13
Ardelyx Inc stock is traded at $4.82, with a volume of 5.01M.
It is up +2.77% in the last 24 hours and down -2.03% over the past month.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
See More
Previous Close:
$4.69
Open:
$4.63
24h Volume:
5.01M
Relative Volume:
1.21
Market Cap:
$1.14B
Revenue:
$251.85M
Net Income/Loss:
$-72.58M
P/E Ratio:
-40.17
EPS:
-0.12
Net Cash Flow:
$-63.80M
1W Performance:
-7.66%
1M Performance:
-2.03%
6M Performance:
-18.17%
1Y Performance:
-18.86%
1-Day Range:
$4.58
$4.96
1-Week Range:
$4.32
$5.4695
52-Week Range:
$4.32
$10.13
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
4.82 | 1.14B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Ardelyx: A Small Bet Its Latest Setback Will Be Temporary (NASDAQ:ARDX) - Seeking Alpha
Ardelyx stock hits 52-week low at $4.34 amid market challenges - Investing.com Canada
Ardelyx (NASDAQ:ARDX) Sets New 1-Year LowShould You Sell? - MarketBeat
Ardelyx (NASDAQ:ARDX) Shares Down 6.5%Here's What Happened - MarketBeat
State Street Corp Acquires 176,789 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - The Eastern Progress Online
Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - The Eastern Progress Online
Ardelyx, Inc. (NASDAQ:ARDX): Is Breakeven Near? - Yahoo Finance
Ardelyx (ARDX) Sees Its Depressed Stock Turning Around - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - The Eastern Progress Online
Lost Money on Ardelyx, Inc.(ARDX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - The Eastern Progress Online
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - The Eastern Progress Online
Levi & Korsinsky Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineARDX - The Eastern Progress Online
ARDX LAWSUIT ALERT: The Gross Law Firm Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - The Eastern Progress Online
Ardelyx, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts against Ardelyx, Inc - The Eastern Progress Online
ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Ardelyx CEO Michael Raab sells $131,620 in stock By Investing.com - Investing.com South Africa
Ardelyx CEO Michael Raab sells $131,620 in stock - Investing.com India
Ardelyx, Inc. (NASDAQ:ARDX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - The Eastern Progress Online
Faruqi & Faruqi Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - The Eastern Progress Online
Objective long/short (ARDX) Report - Stock Traders Daily
Hyperphosphatemia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx - The Globe and Mail
Ardelyx, Inc. (NASDAQ:ARDX): Are Analysts Optimistic? - Simply Wall St
BNP Paribas Financial Markets Boosts Position in Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Ardelyx, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsCXM - The Eastern Progress Online
Ardelyx FY2027 EPS Estimate Increased by Leerink Partnrs - MarketBeat
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ardelyx Inc Stock (ARDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | President & CEO |
Dec 10 '24 |
Sale |
5.26 |
25,000 |
131,620 |
1,150,385 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):